CorVel
CRVL
76.49
+0.66
+0.87%
CorVel
US · CRVL
#2309 by market cap
Listed 1970
76.49
+0.66
+0.87%
Live - 5344 symbols - heartbeat 554s ago
· 2026-10-07 19:54
After-hours
76.49
0.00%
- Market cap
- 3.86B
- P/E (TTM)i
- 34.00
- P/Bi
- 9.45
- EPSi
- 2.14
- Div yieldi
- 0.00%
- 52W posi
- 92%
Reader sentiment
Are you bullish or bearish on CRVL?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 14.19, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +7.03% YoY
Margins
- Gross margin
- 24.29%
- Operating margin
- 14.93%
- Net margin
- 11.51%
Key ratios & quality
- PEG ratioi
- 1.84
- Altman Z-Scorei
- 14.19
PEG uses trailing P/E against the 3-year net income growth rate (18.47%/yr) since forward earnings estimates aren't available here, so this is not a "forward PEG." Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 595.74M | 592.23M | 552.64M | 646.23M | 718.56M | 795.31M | 895.59M | 958.53M |
| Gross profit | 124.81M | 125.92M | 123.62M | 152.11M | 158.26M | 171.69M | 209.73M | 232.86M |
| Selling & admin expenses | 63.30M | 65.21M | 64.45M | 67.60M | 73.71M | 76.59M | 88.90M | 89.73M |
| Research & development | -- | -- | -- | -- | -- | -- | -- | -- |
| Operating profit | 61.51M | 60.71M | 59.18M | 84.51M | 84.55M | 95.10M | 120.82M | 143.13M |
| Pretax profit | 61.51M | 60.71M | 59.18M | 84.51M | 84.55M | 95.10M | 120.82M | 143.13M |
| Tax | 14.81M | 13.33M | 12.82M | 18.10M | 18.19M | 18.85M | 25.66M | 32.79M |
| Net profit | 46.70M | 47.38M | 46.36M | 66.41M | 66.37M | 76.25M | 95.17M | 110.34M |
| Basic EPS | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 |
| Diluted EPS | 0.82 | 0.85 | 0.85 | 1.22 | 1.26 | 1.47 | 1.83 | 2.14 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 231.51M | 234.71M | 239.64M | 235.63M | 248.55M | 259.93M |
| Gross profit | 58.18M | 56.76M | 58.18M | 54.92M | 63.01M | 67.79M |
| Selling & admin expenses | 24.86M | 21.48M | 22.28M | 22.68M | 23.29M | 24.45M |
| Research & development | -- | -- | -- | -- | -- | -- |
| Operating profit | 33.32M | 35.28M | 35.90M | 32.23M | 39.72M | 43.34M |
| Pretax profit | 33.32M | 35.28M | 35.90M | 32.23M | 39.72M | 43.34M |
| Tax | 6.90M | 8.05M | 7.99M | 8.06M | 8.69M | 11.12M |
| Net profit | 26.42M | 27.24M | 27.91M | 24.17M | 31.03M | 32.23M |
| Basic EPS | 1 | 1 | 1 | 0 | 1 | 1 |
| Diluted EPS | 0.51 | 0.52 | 0.54 | 0.47 | 0.61 | 0.63 |
Balance sheet
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 215.49M | 208.99M | 268.94M | 264.99M | 243.77M | 302.23M | 386.69M | 462.30M |
| Cash & ST investments | 91.71M | 83.22M | 139.72M | 97.50M | 71.33M | 105.56M | 170.58M | 233.07M |
| Inventory | -- | -- | -- | -- | -- | -- | -- | -- |
| Total assets | 318.02M | 416.26M | 424.76M | 415.25M | 393.92M | 454.68M | 545.98M | 642.99M |
| Total current liabilities | 116.92M | 133.69M | 162.46M | 171.37M | 167.89M | 184.50M | 204.04M | 228.07M |
| Short-term debt | 5.71M | 13.22M | 12.77M | 13.35M | 9.90M | 8.86M | 8.13M | 7.42M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 123,213,000.00 | 226,549,000.00 | 204,358,000.00 | 202,851,000.00 | 191,747,000.00 | 207,032,000.00 | 223,989,000.00 | 248,755,000.00 |
| Total equity | 194.81M | 189.71M | 220.40M | 212.40M | 202.18M | 247.65M | 321.99M | 394.23M |
| Retained earnings | 505.16M | 552.54M | 598.89M | 665.30M | 731.67M | 807.92M | 903.09M | 1.01B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 386.69M | 421.62M | 434.27M | 463.92M | 462.30M | 504.78M |
| Cash & ST investments | 170.58M | 202.03M | 207.45M | 230.03M | 233.07M | 255.88M |
| Inventory | -- | -- | -- | -- | -- | -- |
| Total assets | 545.98M | 597.45M | 611.68M | 644.79M | 642.99M | 689.74M |
| Total current liabilities | 204.04M | 235.22M | 230.33M | 250.45M | 228.07M | 260.06M |
| Short-term debt | 8.13M | 7.73M | 7.32M | 7.33M | 7.42M | 7.61M |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 223,989,000.00 | 254,916,000.00 | 248,904,000.00 | 269,063,000.00 | 248,755,000.00 | 280,843,000.00 |
| Total equity | 321.99M | 342.53M | 362.78M | 375.72M | 394.23M | 408.89M |
| Retained earnings | 903.09M | 930.32M | 958.23M | 982.40M | 1.01B | 1.05B |
Cash flow
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | 78.64M | 80.83M | 94.38M | 67.22M | 82.29M | 99.24M | 127.32M | 155.64M |
| Depreciation & amortization | 22.98M | 22.52M | 23.44M | 23.92M | 25.12M | 26.25M | 29.54M | 31.76M |
| Free cash flow | 63.37M | 48.47M | 77.14M | 37.40M | 55.97M | 70.00M | 91.56M | 110.28M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -35.17M | -65.61M | -32.67M | -90.09M | -93.68M | -45.71M | -37.61M | -56.21M |
| Ending cash balance | 91.71M | 83.22M | 139.72M | 97.50M | 71.33M | 105.56M | 170.58M | 233.07M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | 22.92M | 55.01M | 25.02M | 46.14M | 29.47M | 49.92M |
| Depreciation & amortization | 7.60M | 7.59M | 7.84M | 8.07M | 8.27M | 8.76M |
| Free cash flow | 14.26M | 39.55M | 15.27M | 35.17M | 20.29M | 43.09M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -9.00M | -9.62M | -12.84M | -13.55M | -20.20M | -21.97M |
| Ending cash balance | 170.58M | 202.03M | 207.45M | 230.03M | 233.07M | 255.88M |
Returns & efficiency
| Line item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | 25.52 | 24.64 | 22.61 | 30.69 | 32.02 | 33.90 | 33.41 | 30.81 |
| ROA %i | 15.78 | 12.90 | 11.02 | 15.81 | 16.40 | 17.97 | 19.02 | 18.56 |
| ROIC %i | 25.52 | 16.30 | 16.46 | 25.03 | 27.01 | 29.61 | 30.25 | 28.57 |
| 5-year avg ROE %i | 22.96 | 23.39 | 23.52 | 25.30 | 27.10 | 28.77 | 30.53 | 32.17 |
| EBIT margin %i | 10.33 | 10.25 | 10.71 | 13.08 | 11.77 | 11.96 | 13.49 | 14.93 |
| FCF / sales %i | 10.64 | 8.18 | 13.96 | 5.79 | 7.79 | 8.80 | 10.22 | 11.51 |
| Current ratioi | 1.84 | 1.56 | 1.66 | 1.55 | 1.45 | 1.64 | 1.90 | 2.03 |
| Quick ratioi | 1.39 | 1.11 | 1.26 | 1.05 | 0.91 | 1.10 | 1.35 | 1.47 |
| Debt / assetsi | 1.79 | 23.62 | 12.87 | 10.39 | 8.57 | 6.91 | 5.14 | 4.37 |
| LT debt / equityi | -- | 44.86 | 19.01 | 14.03 | 11.80 | 9.10 | 6.20 | 5.25 |
| Interest coveragei | -- | -- | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | 5.76 | 4.52 | -0.34 | 2.75 | 6.66 | 12.90 | 11.49 | 10.08 |
| Net income CAGR (3Y) %i | 17.86 | 17.13 | 9.10 | 12.45 | 11.89 | 18.05 | 12.74 | 18.47 |
| FCF CAGR (3Y) %i | 22.40 | 32.13 | 30.81 | -16.11 | 4.91 | -3.19 | 34.77 | 25.37 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | 33.41 | 33.25 | 32.63 | 31.26 | 30.81 | 30.70 |
| ROA %i | 19.02 | 18.61 | 18.64 | 17.87 | 18.56 | 17.92 |
| ROIC %i | 30.25 | 30.36 | 29.96 | 28.89 | 28.57 | 28.58 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | 13.49 | 13.94 | 14.49 | 14.52 | 14.93 | 15.37 |
| FCF / sales %i | 10.22 | 10.71 | 10.84 | 11.07 | 11.51 | 11.57 |
| Current ratioi | 1.90 | 1.79 | 1.89 | 1.85 | 2.03 | 1.94 |
| Quick ratioi | 1.35 | 1.29 | 1.36 | 1.33 | 1.47 | 1.41 |
| Debt / assetsi | 5.14 | 4.59 | 4.23 | 4.02 | 4.37 | 4.12 |
| LT debt / equityi | 6.20 | 5.75 | 5.12 | 4.95 | 5.25 | 5.08 |
| Interest coveragei | -- | -- | -- | -- | -- | -- |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
✦ Quant Revenue Concentration how this is computed
Lead segment, long tail
- Patient management services is the largest reported line at 61.28% of revenue, across 2 reported segments.
- Network solutions services follows at 38.72%, so the top line still matters most but isn’t the whole story.
Revenue breakdown most recent period
Business
Patient management services61.28%
Network solutions services38.72%
Quote time 2026-10-07 19:54:59 · For reference only, not investment advice and not tailored to your situation.